Solid Biosciences (SLDB) announced that the FDA has granted orphan drug designation to SGT-212 for the treatment of Friedreich’s ataxia.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences doses first participant in Phase 1b FALCON trial on SGT-212
- These Are the Most and Least Likely Biotech Takeover Targets for 2026
- Solid Biosciences announces Duchenne muscular dystrophy added to HHS RUSP
- HHS adds Duchenne muscular dystrophy to recommended screening panel
- Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Progress Drive Buy Rating